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PCSK9 induces a pro-inflammatory 
response in macrophages
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Intraplaque release of inflammatory cytokines from macrophages is implicated in atherogenesis by 
inducing the proliferation and migration of media smooth muscle cells (SMCs). PCSK9 is present and 
released by SMCs within the atherosclerotic plaque but its function is still unknown. In the present 
study, we tested the hypothesis that PCSK9 could elicit a pro-inflammatory effect on macrophages. 
THP-1-derived macrophages and human primary macrophages were exposed to different 
concentrations (0.250 ÷ 2.5 µg/ml) of human recombinant PCSK9 (hPCSK9). After 24 h incubation with 
2.5 µg/ml PCSK9, a significant induction of IL-1β, IL-6, TNF-α, CXCL2, and MCP1 mRNA, were observed 
in both cell types. Co-culture of THP-1 macrophages with HepG2 overexpressing hPCSK9 also showed 
the induction of TNF-α (2.4 ± 0.5 fold) and IL-1β (8.6 ± 1.8 fold) mRNA in macrophages. The effect 
of hPCSK9 on TNF-α mRNA in murine LDLR−/− bone marrow macrophages (BMM) was significantly 
impaired as compared to wild-type BMM (4.3 ± 1.6 fold vs 31.1 ± 6.1 fold for LDLR−/− and LDLR+/+, 
respectively). Finally, a positive correlation between PCSK9 and TNF-α plasma levels of healthy 
adult subjects (males 533, females 537) was observed (B = 8.73, 95%CI 7.54 ÷ 9.93, p < 0.001). Taken 
together, the present study provides evidence of a pro-inflammatory action of PCSK9 on macrophages, 
mainly dependent by the LDLR.
The constant and slow development of the atherosclerotic plaque is driven by a failure to resolve the inflamma-
tory response in the arterial wall initiated by the retention of apolipoprotein B (apoB)-containing lipoproteins, 
mainly the low-density lipoproteins (LDL)1. LDL retained in the arterial wall undergo chemical oxidation and 
then capture, through the scavenger receptors, by infiltrated macrophages, which ultimately become foam cells. 
The continuing accumulation of LDL fuels not only the formation of foam cells, but also a chronic amplification 
of the inflammatory response, the main cause of plaque rupture and vascular thrombosis2.
The study of the central role of macrophages in atherogenesis led to the observation of the presence of 
two different macrophage populations that can be grossly divided into pro-inflammatory (M1 cells) and 
anti-inflammatory (M2 cells) based mainly on in vitro criteria3. Polarization toward the M1 state is induced by 
several stimuli in vitro, including Toll-like receptor (TLR) ligands (such as lipopolysaccharide, LPS) and inter-
feron γ.
M1 macrophages express several pro-inflammatory mediators, such as inducible nitric oxide synthase, tumor 
necrosis factor-α (TNF-α), interleukin-1β (IL-1β), IL-6, IL-12, and proteolytic enzymes3. The presence of M1 
macrophages has been demonstrated in both human and mouse atherosclerotic plaques and is considered the 
main intravascular source of pro-inflammatory cytokines, responsible for the maintenance of local inflammation 
and for the extracellular matrix components degradation, thus promoting the disease progression3.
Since LDL-cholesterol represents the most validated risk factor for atherosclerosis, several studies have tried 
to address the relationship between cholesterol and inflammation. Among the different mechanisms that have 
been postulated, one points toward the increase of plasma membrane cholesterol through the involvement of the 
TLRs4,5. Despite this evidence, a number of studies show opposite results, such as an anti-inflammatory pheno-
type induced by intracellular cholesterol6.
Proprotein convertase subtilisin kexin type 9 (PCSK9) represents the most effective mediator of the 
LDL receptor degradation and thus a main regulator of the LDL-cholesterol homeostasis7. We have previously 
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shown that PCSK9 is present in the atherosclerotic plaque and that the LDL receptor (LDLR) expression in mac-
rophages is influenced by PCSK9 derived from smooth muscle cells8.
Interestingly, the PCSK9 knock-down in macrophages partially blunted the induction of pro-inflammatory 
cytokines in response to oxLDL9. The role of PCSK9 as a pro-inflammatory mediator is also supported by the 
observation that increased LDLR expression is associated with protection from severe sepsis10 and, more impor-
tantly, the PCSK9 null mice displayed blunted systemic responses to LPS treatment11. Furthermore, exogenous 
overexpression of PCSK9 in macrophages enhanced the response to LPS, increasing the expression of IL1β and 
TNF-α and decreasing the anti-inflammatory markers Arg1 and IL-1012. Finally, the suppression of PCSK9 
expression in the atherosclerotic plaques of apoE null mice, by means of lentivirus-mediated PCSK9 shRNA, 
reduced macrophage infiltration and decreased expression of TNF-α, IL-1β, MCP-1, toll-like receptor 4 (TLR-4) 
and nuclear factor kappa B (NF-κB)13.
In the present study, we investigated the role of PCSK9 on the inflammatory state of macrophages. We demon-
strated that recombinant human PCSK9 induced a pro-inflammatory phenotype, by increasing the expression 
of inflammatory cytokines (TNF-α, IL-1β, IL-6) and chemokines (Monocyte Chemotactic Protein 1, MCP1 
and Chemokine C-X-C motif ligand 2, CXCL2) in human THP1 and primary macrophages, as well as in bone 
marrow derived macrophages (BMM). Similar results were observed by using a co-cultured system with HepG2 
cells overexpressing PCSK9 and THP-1-derived macrophages. Finally, by using BMM from genetically modified 
mice, we demonstrated that the response to PCSK9 is mainly, but not entirely, dependent on the presence of the 
LDLR. The clinical relevance of our observation is supported by the positive correlation found in the plasma levels 
of PCSK9 and TNF-alpha of subjects enrolled in the Brisighella Heart Study.
Material and Methods
Reagents and antibodies. RPMI media was obtained by Sigma, penicillin, streptomycin, nonessential 
amino acid solution, Fetal Calf Serum (FCS), disposable culture flasks and petri dishes were from Euroclone. 
Molecular weight protein standards, SDS, TEMED, ammonium persulfate, glycine, and acrylamide solution 
(30%T, 2.6%C) were from BIO-RAD Laboratories. BCA assay for determination of protein concentrations was 
purchased from Thermo Scientific. Tumor Necrosis Factor-α (TNF-α) was purchased from Sigma. Recombinant 
hPCSK9 was obtained by Vinci Biochem (BPS Biosciences, San Diego CA USA). The recombinant PCSK9 was 
formulated in 40 mM Tris-HCl, pH 8.0, 110 mM NaCl, 2.2 mM KCl, and 20% glycerol. The endotoxin level of 
hPCSK9 was 84.8 EU/mL or 47 EU/mg, below the threshold of 0.1 EU/µg requested for cell based assays. The JAK 
inhibitor JAK1 was purchased from Millipore and fatostatin hydrobromide from Sigma. The JAK inhibitor is a 
highly potent, ATP-competitive inhibitor of JAK with IC50 values equal to 15, 1, 5 and 1 nM for JAK1, 2, 3 and 
Tyk2, respectively.
Cell culture. THP1-derived macrophages. THP-1 monocyte cells were cultured in RPMI media sup-
plemented with penicillin (10,000 U/mL), streptomycin (10 mg/mL), nonessential amino acid, 10% (FCS and 
β-mercaptoethanol 0.05 mM. To obtain THP-1 macrophages, THP-1 monocytes were seeded in appropriate mul-
tiwell plate and treated with Phorbol 12-myristate 13-acetate (PMA; 3.2 × 10–7 M) for 72 h. Then, macrophages 
were treated for 24 h with PCSK9 0.25, 0.5, 1 and 2.5 ug/ml, using TNF-α 10 ng/ml as positive control.
Preparation of Human Macrophages. Human monocytes were obtained from healthy donors who gave their 
informed consent to participate in the study. Blood sampling - Venous blood samples were obtained by veni-
puncture of the antecubital vein with a 19 G needle without venous stasis. After discarding the first 4 ml, blood 
was drawn into 4 ACD-containing vacutainers (Becton Dickinson, CA, USA) for monocyte isolation and into 
one Z-vacutainer (Becton Dickinson, Ca, USA) for serum preparation. Haemocrome was assessed by Sysmex 
XS-1000i haematologic analyzer (Kobe).
Serum preparation. Serum was obtained by incubating blood at 37 °C for 1 hour followed by centrifugation at 
1700 g, 10 minutes, 4 °C and transferred under sterile conditions into a new tube and stored at 4 °C until use.
Monocytes isolation. Immediately after withdrawal, ACD-anticoagulated blood was centrifuged at 100 g, 10 min-
utes at room temperature. The platelet rich-plasma was completely removed and the remaining blood was mixed 
with RPMI (Lonza, 1640) containing 0,1% L-glutammine (Thermo Fisher), 0.5% Pen-strep (Thermo Fisher), 
20% FCS and 0.38% sodium citrate (Sigma) to restore the initial volume of blood in the tubes. Mononuclear cells 
were isolated by Ficoll-Paque Plus (GE Healthcare, vWR Int.) density centrifugation at 600 g, 20 minutes at room 
temperature with no brake. Cells were washed with PBS containing 0, 1% glucose (Sigma), 0, 5% BSA (Sigma) 
and 5 mM EDTA and centrifuged at 830 g for 10 minutes at 4 °C with brake. Cells were further washed twice in 
PBS without EDTA and centrifuged at 350 g for 10 minutes at 4 °C with brake. Mononuclear cells resuspended 
in RPMI supplemented with 10% autologous serum, 0, 1% L-glutammine and 0.5% Pen-strep were then plated 
(100.000 monocytes/100 µl) in a 48 Well Cell Culture Plate and incubated at 37 °C. After 2 hours cells were washed 
3 times with PBS in order to remove non-adherent lymphocytes; adherent monocytes were then cultured in the 
same medium over 7 days at 37 °C (5% CO2). Medium was not replaced throughout the culture period.
Bone marrow derived macrophages (BMM). Bone marrow macrophages were collected from the femur and 
tibia of C57BL/6 or LDLR−/− mice (from Envigo and The Jackson Laboratories respectively). All experiments 
were conducted in conformity with the Public Health Service Policy on the Humane Care and Use of Laboratory 
Animals and performed with the approval of the Ethical Committee for Animal Experiments of the University 
of Parma. After isolation, cells were seeded in 24-well plates in high glucose DMEM containing 30% L-929 cells 
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conditioned medium and 10% FCS and maintained at 37 °C, 5% CO2. After 4 days, non-adherent cells were 
removed and fresh medium was added. After 3 further days, cells were differentiated and treated according to the 
protocol.
HepG2 and THP-1 co-culture. HepG2 or HepG2PCSK9 were cultured with THP-1 monocytes by using a trans-
membrane system (Transwell) of polycarbonate membrane with 0.4 μm pores. HepG2 and HepG2PCSK9 cells were 
seeded in 6-well plates at a density of 6 × 105 cells/well in MEM + 10% FCS. After 3 days, HepG2 and HepG2PCSK9 
medium was discarded and THP-1 cells, suspended in fresh medium, were added in the transmembrane system 
to each well seeded with HepG2 or HepG2PCSK9, at a density of 2 × 105 cells/well.
Quantitative real time PCR (qRT-PCR) assay. Total mRNA was extracted by using iScript Sample Preparation 
Reagent (BIO-RAD laboratories), according to manufacturer’s instructions. Reverse transcription-polymerase 
first-strand cDNA synthesis was performed by using the iScript cDNA synthesis Kit (BIO-RAD laboratories) 
and for qRT-PCR were used the Kit Thermo Sybr Green/ROX qPCR Master Mix (Carlo Erba Reagents S.r.l.) and 
specific primers of the genes of interest (described below). The analyses were performed with the ABI Prism® 
7000 Sequence Detection System (Applied Biosystems), as previously described14. PCR cycling conditions were 
as follows: 94 °C for 3 min, 40 cycles at 94 °C for 15 s, and 60 °C for 1 min. Data were expressed as Ct values and 
used for the relative quantification of targets with the ΔΔCt calculation. Primer sequences used for qRT-PCR 
analysis are shown in Table 1.
ELISA assay. Conditioned media from treated cells were collected and used for the protein quantification of 
PCSK9, IL-6 and TNF-α by ELISA kit (Quantikine ELISA Kit, R&D Systems), as previously described15.
Western Blot analysis. Total cytosolic protein extracts were obtained by collecting cells in 200 μl of Mammalian 
Protein Extraction Reagents (Thermo Fisher Scientific) containing a cocktail of protease and phosphatase inhib-
itors (Roche Diagnostics S.p.A.). Molecular mass marker (Novex® Sharp Protein Standard, InvitrogenTM; Life 
Technologies Europe BV) and proteins were separated through 10–12% SDS-PAGE gel. Proteins were then trans-
ferred to a nitrocellulose membrane and blocked with albumin buffer containing 0.05% of Tween20. Incubation 
with primary antibodies occurred overnight at 4 °C with the following antibodies: LDLR rabbit Polyclonal 
Antibody 1:200 (Cayman Chemical) and α-tubulin 1:5000 (Sigma). Membrane was incubated with anti-mouse 
and anti-rabbit peroxidase-conjugated secondary antibodies (1:5000) (Jackson ImmunoResearch Lab). 
Immunoreactive bands were detected by acquiring images with Odyssey® (LI-COR Biosciences). Densitometric 
readings were evaluated using the Image Studio Software, as previously described16.
Immunocytochemistry. Cells were fixed in 4% paraformaldehyde at room temperature for 10 min, permeabilized 
in 0.1% Triton X-100 in PBS for 5 min, and incubated for 1 h with 1% bovine serum albumin (BSA). Cells were 
then incubated with primary antibody anti NF-κB p65 (Rabbit polyclonal GeneTex) for 1 h at room temperature, 
followed by three washes with PBS and subsequent incubation with Alexafluor®−568 anti-rabbit antibody. Cells 
were then washed four times with PBS, incubated with DAPI solution for 5 min, mount and coversliped with 
Vectashield. Immunostaining of cells was analyzed by fluorescent confocal microscope (Zeiss LSM 800).
Subjects. Study participants were patients enrolled in the Brisighella Heart Study. All the involved subjects have 
signed an informed consent form. The Brisighella Heart Study protocol and its substudies have been evaluated 
and approved by the Ethical Board of the S. Orsola-Malpighi University Hospital (Bologna, Italy). All experi-
ments were performed in accordance with relevant guidelines and regulations. We selected a sample of overall 
Primer Forward Reverse
18S 5′-CGGCTACCACATCCACGGAA-3′ 5′-CCTGTATTGTTATTTTTCGTCACTACC-3′
human
hIL-6 5′-GGTACATCCTCGACGGCATCT-3′ 5′-GTGCCTCTTTGCTGCTTTCAC
hIL-1β 5′-ATGCACCTGTACGATCACTG-3′ 5′-ACAAAGGACATGGAGAACACC-3′
hTNF-α 5′-ACTTTGGAGTGATCGGCC-3′ 5′-GCTTGAGGGTTTGCTACAAC-3′
hCXCL2 5′-CGCCCATGGTTAAGAAAATCA-3′ 5′-CCTTCTGGTCAGTTGGATTTGC-3′
hMCP1 5′-CGCCTCCAGCATGAAAGTCT-3′ 5′-GGAATGAAGGTGGCTGCTATG-3′
hPCSK9 5′-CCTGCGCGTGCTCAACT-3′ 5′-GCTGGCTTTTCCGAAACTCT-3′
hLDLR 5′-GTGTCACAGCGGCG-3′ 5′-CGCACTCTTTGATG-3′
mouse
mIL-6 5′-GAGGATACCACTCCCAACAGACC-3′ 5′-AAGTGCATCATCGTTGTTCATACA-3′
mIL-1β 5′-CAACCAACAAGTGATATTCTCCATG-3′ 5′-GATCCACACTCTCCAGCTGCA-3′
mTNF-α 5′-CCCTCACACTCAGATCATCTTCT-3′ 5′-GCTACGACGTGGGCTACAG-3′
mCXCL2 5′-CCAAGGGTTGACTTCAAGAAC-3′ 5′-AGCGAGGCACATCAGGTACG-3′
mMCP-1 5′-ACCACAGTCCATGCCATCAC-3′ 5′-TTGAGGTGGTTGTGGAAAAG-3′
mLDLR 5′-GTGTGACCGTGAACATGACTGC-3′ 5′-CACTCCCCACTGTGACACTTGA-3′
Table 1. Primer sequence utilized for the qRT-PCR analysis.
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healthy adult subjects (M: 533, F: 537), after exclusion of active smokers, subjects affected by chronic inflam-
matory disorders (including atopic diseases) and subjects chronically assuming non-steroidal antinflammatory 
drugs, systemic corticosteroids, or immunosuppressants17. A Pearson’s bivariate correlation followed by a mul-
tiple linear regression have been carried out to evaluate the potential relationship between TNF-α and PCSK9 
plasma levels in humans.
Statistical analysis. Statistical analysis was performed using the Prism statistical analysis package version 
5.01 (GraphPad Software). Data are given as mean ± SD of three independent experiments. When possible, 
p-values were determined by Student’s t-test. Otherwise, differences between treatment groups were evaluated by 
1-way ANOVA. A probability value of p < 0.05 was considered statistically significant.
Results
To test the hypothesis that PCSK9 could have a pro-inflammatory effect on macrophages, we first performed 
a series of experiments with macrophages derived from human monocyte cell line THP-1 incubated with 
increasing concentrations of human recombinant PCSK9. The incubation for 24 h induced the mRNA levels of 
pro-inflammatory cytokines IL-1β, IL-6 and TNF-α, markers of M1 phenotype (Fig. 1A–C). In particular, the 
effect of hPCSK9 on IL-1β appears to be concentration-dependent, with a significant induction starting from 
250 ng/ml (Fig. 1A). The mRNA levels of TNF-α also increased in a concentration-dependent manner, although 
we observed a consistent lower effect at 1 µg/ml than lower concentrations and a maximal effect at 2.5 µg/ml 
(3.3 ± 0.7 fold) (Fig. 1B). Differently, hPCSK9 strongly induced IL-6 mRNA levels exclusively at 2.5 µg/ml 
(36.4 ± 19.3 fold), with no effect at 250 ng/ml, 0.5 µg/ml and 1 µg/ml (Fig. 1C).
The determination of mRNA levels of monocyte chemokines, such as MCP-1 and CXCL2, also revealed a 
positive effect of hPCSK9 (Fig. 1D,E), with a concentration dependent response for MCP-1 (similar to IL1-β) and 
a strong induction at 2.5 µg/ml for CXCL2 (similar to TNF-α). In all the experiments, THP1 macrophages were 
also incubated with TNF-α (10 ng/ml) as positive control. Interestingly, the effect of 250 ng/ml hPCSK9, thus 
within its physiological plasma concentrations (median 270 ng/mL, ranging from 91 to 804 ng/ml18), exerted a 
similar pro-inflammatory effect than TNF-α.
Since transcription of the majority of proinflammatory cytokines are under the control of NF-κB transcription 
factor, we investigated the effect of PCSK9 on the nuclear localization of p65 subunit in THP-1 derived mac-
rophages. As expected, the incubation with TNF-α induced a marked response of NF-κB activation with positive 
nuclear staining of p65 cells NF-κB in approximately 30% of the cells, while no nuclear staining was observed 
under basal condition. Interestingly, the incubation with 2.5 µg/ml of PCSK9 induced a significant NF-κB activa-
tion, with 16% of the cells with positive nuclear staining for p65 (Fig. 1F).
To extend our observation, we performed the same analysis on human macrophages derived from blood of 
healthy volunteers. A concentration-dependent effect of hPCSK9 on mRNA levels of IL-1β, IL-6 and TNF-α 
was observed, with a significant induction at 1 µg/ml and 2.5 µg/ml for all genes (Fig. 2). As observed with THP-
1, hPCSK9 induced IL-1β also at 250 ng/ml. A significant increase of MCP1 and CXCL2 mRNA levels were 
observed after incubation with 2.5 µg/ml of hPCSK9 (Fig. 2).
To further validate our observation, we determined the effect of hPCSK9 on IL1-β and IL-6 released by human 
macrophage in the cultured media, by ELISA assay. As shown in Fig. 3, 24 h incubation with 2.5 µg/ml hPCSK9 
significantly increased both IL-6 and TNF-α concentration (3.6 ± 1.3 fold and 4.5 ± 0.2 fold, respectively).
Overall, recombinant hPCSK9 induced a pro-inflammatory response in both THP1 and human macrophages, 
showing a robust induction of mRNA of IL-1β, IL-6, TNF-α, MCP1, CXCL2, and an increased IL-1β and TNF-α 
released from human macrophages.
To further corroborate our results, we investigated a possible correlation between PCSK9 and TNF-α plasma 
levels from a selected overall healthy adult subjects (males 533, females 537) enrolled in the Brisighella Heart 
Study17. The main characteristics of the selected subjects are summarized in Table 2. The Pearson’s bivariate cor-
relation between TNF-α and PCSK9 showed a correlation coefficient of 0.388 with a p < 0.001 (Fig. 3C). After 
adjustment for age, gender, and BMI, in the multiple linear analysis, TNF-α and PCSK9 plasma levels were signif-
icantly related (B = 8.73, 95% CI 7.54 ÷ 9.93, p < 0.001) (Fig. 3C). This evidence further supports a relationship 
between chronic inflammation and PCSK9 levels.
To further establish the pro-inflammatory effect of PCSK9, we performed co-cultured experiments of THP-1 
macrophages and HepG2 control or overexpressing PCSK9. HepG2 were transduced with pBM-IRES-PURO 
retrovirus encoding control vector (PURO) or human PCSK9. After puromycin selection, we measured the 
amount of PCSK9 released in the cultured media by ELISA assay. While control HepG2 cells released 1.7 ng/ml 
of PCSK9, the HepG2PCSK9 reached approximately 10 ng/ml (9.0 ± 1.0 ng/ml) (Fig. 4A). The co-culture with 
THP1 macrophage revealed that the exposure to conditioned media from HepG2PCSK9 significantly induced 
the pro-inflammatory genes TNF-α and IL-1β by 2.4 ± 0.5 fold and 8.6 ± 1.8 fold, respectively, as compared to 
HepG2 (Fig. 4B,C).
Since the main molecular target of PCSK9 is the LDLR, we performed the same analysis on bone marrow 
macrophages (BMM) isolated from C57BL/6 and LDLR−/− mice. The incubation of BMM LDLR+/+ with increas-
ing concentrations of hPCSK9 determined a significant induction of the LDLR mRNA (Fig. 5A), and a down-
regulation of LDLR (−33% at 2.5 µg/ml of hPCSK9), as assessed by western blot analysis (Fig. 5B). Under the 
same experimental conditions, BMM LDLR+/+ respond to 2.5 µg/ml hPCSK9 by increasing the expression of 
TNF-α (31.1 ± 6.1 fold), while no significant effect was observed at lowest PCSK9 concentrations (Fig. 5C). 
Interestingly, the BMM LDLR−/− showed only a marginal increase of TNF-α expression (4.3 ± 1.6 fold), which 
is significantly lower than that observed in BMM LDLR+/+. The different response to hPCSK9 is further vali-
dated by the fact that both macrophage types respond at similar extent to TNF-α (5.7 ± 1.5 vs 4.9 ± 0.3 fold in 
BMM LDLR+/+ and BMM LDLR−/−, respectively) (Fig. 5C). Taken together, the present results suggest that the 
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pro-inflammatory response of PCSK9 on macrophages is mainly, but not exclusively, dependent on the pres-
ence of the LDLR. Interestingly, the pharmacological inhibition of Janus Kinase (JAK)/Signal Transducer and 
Activator of Transcription (STAT) signaling, by a JAK inhibitor, and the SREBP pathway, by fatostatin, completely 
prevented the induction of the TNF-α mRNA by PCSK9 (Fig. 5D).
Figure 1. Recombinant hPCSK9 induces the expression of pro-inflammatory cytokines and chemokines in 
THP-1 derived macrophages. THP-1 macrophages were incubated for 24 h with TNF-α 10 ng/ml (as positive 
control) or different concentrations of recombinant hPCSK9 (0.25, 0.5, 1 and 2.5 μg/ml). At the end of the 
incubation, total RNA was extracted and (A) IL-1β, (B) TNF-α, (C) IL-6, (D) MCP-1 and (E) CXCL2 mRNA 
expression was determined by qRT-PCR. (F) THP-1 macrophages were incubated with TNF-α 10 ng/ml (as 
positive control) and recombinant hPCSK9 (2.5 μg/ml). After 24 h cells were fixed and immunostaining was 
performed for NF-κB p65 (blue: nuclei; green: p65 NF-κB). Arrows indicate cells with positive nuclear staining 
of p65. Data are given as mean ± SD of three independent experiments. Differences vs basal were assessed by 
Student’s t-test: *p < 0.05; **p < 0.01; ***p < 0.001.
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Discussion
In the present report, we demonstrated that human recombinant PCSK9 drives an inflammatory response on 
macrophages by inducing the pro-inflammatory cytokines TNF-α, IL-1 and IL-6, and the chemokines MCP-1 
and CXCL2. This effect was observed in THP-1, human primary, and murine bone marrow-derived macrophages. 
In addition, the inflammatory response was observed when THP-1 macrophages were co-cultured with HepG2 
cells overexpressing PCSK9. This data excludes the possibility that endotoxin contamination of human recombi-
nant PCSK9 can be responsible for the pro-inflammatory effect observed. Finally, we found a positive correlation 
between plasma levels of PCSK9 and TNF-α, in a population of overall healthy subjects17,19, an observation that 
further supports the role of PCSK9 on inflammation.
Figure 2. Recombinant hPCSK9 induces the expression of pro-inflammatory cytokines and chemokines in 
human macrophages. Human macrophages were incubated for 24 h with TNF-α 10ng/ml (as positive control) 
or different concentrations of recombinant hPCSK9 (0.25, 0.5, 1 and 2.5 μg/ml). At the end of the incubation, 
total RNA was extracted and (A) IL-1β, (B) IL-6, (C) TNF-α, (D) MCP-1 and (E) CXCL2 mRNA expression 
was determined by qRT-PCR. Data are given as mean ± SD of three independent experiments. Differences vs 
basal were assessed by Student’s t-test: *p < 0.05; **p < 0.01; ***p < 0.001.
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Macrophages present in the atherosclerotic plaque are derived, mainly but not exclusively, from circulating 
monocytes that differentiated into macrophages within the arterial wall20. The main function of macrophages is 
to scavenge lipoprotein particles, and eventually to become foam cells21, which then contribute to a local release 
of inflammatory molecules and factors that further promote lipoprotein retention and extracellular matrix deg-
radation22. Macrophages are very heterogeneous cells that can polarized to different phenotypes in response to 
the environmental cues encountered23. Local cytokines, as well as oxidized LDL, have a very potent effect on 
macrophage polarization24 and our data show that PCSK9 is also capable to influence the pro-inflammatory status 
of macrophages.
The discovery that PCSK9 is present in the atherosclerotic plaque argues a possible local effect on SMCs, mac-
rophages and endothelial cells8. PCSK9 can reach the plaque from the bloodstream, as it binds to lipoproteins25, 
or can be synthesized within the arterial wall from SMCs8,26. Both sources can be theoretically possible since both 
protein and mRNA PCSK9 have been detected in the human atherosclerotic plaques8,25. Although the intraplaque 
concentration of PCSK9 is not known, it is important to underlying that we observed a pro-inflammatory effect 
on macrophages at relatively low concentrations, starting from 250 ng/ml, thus even below the mean plasma levels 
found in observational studies19.
The translation of our findings into experimental atherosclerosis and human pathology still needs to be 
determined. However, alirocumab, an anti PCSK9 monoclonal antibody, has shown to influence the atheroscle-
rotic plaque development towards a more stable characteristic with reduced macrophage content and higher 
Figure 3. Effect of recombinant hPCSK9 on the release of IL-6 and TNF-α from human macrophages. Human 
monocytes were seeded in 6 well plates in RPMI containing 10% of the volunteer autologous serum and 
incubated for 1 week. Human macrophages were then incubated for 24 h with TNF-α 10 ng/ml (as positive 
control) or different concentrations of recombinant hPCSK9 (0.25, 0.5, 1 and 2.5 μg/ml). IL-6 (A) and TNF-α 
(B) protein amount was then assessed by ELISA assay on collected media. Results were expressed as pg of 
protein for ml of media. (C) Relationship between TNF-α and PCSK9 serum levels determined by ELISA 
assay from human samples. Data of panel A and B are given as mean ± SD of three independent experiments. 
Differences vs basal were assessed by Student’s t-test: *p < 0.05; **p < 0.01; ***p < 0.001.
Mean ± SD
AGE 57.66 ± 11.77
BMI 23.33 ± 3.46
SBP 130.02 ± 11.37
DBP 67.78 ± 7.12
TC 218.12 ± 19.38
TG 118.29 ± 69.35
HDL-C 51.97 ± 5.54
LDL-C 141.58 ± 18.31
FPG 93.24 ± 5.61
SUA 5.215 ± 1.29
GOT 23.17 ± 7.59
GPT 24.13 ± 9.32
gGT 25.67 ± 13.47
Creatinine 1.03 ± 0.19
eGFR (CKD-EPI) 81.30 ± 15.41
PCSK9 (ng/ml) 286.25 ± 81.14
TNF alpha (pg/ml) 6.69 ± 3.60
Table 2. Main Characteristics of the Selected Participants.
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deposition of extracellular matrix27. In addition, the treatment with anti PCSK9 monoclonal antibodies reduces 
CCR2 expression and the migratory capacity of circulating monocytes in familial hypercholesterolaemia (FH) 
patients28. This effect seems to be due to a reduction of both LDL-C circulating levels and intracellular lipid 
Figure 4. PCSK9 released from HepG2 increased TNF-α and IL-1β gene expression in THP-1 derived 
macrophages. THP-1 macrophages were co-cultured with HepG2 or HepG2PCSK9 seeded on top of the transwell 
system. After 24 h, total RNA was extracted from THP-1 macrophages and TNF-α and IL-1β gene expression 
was evaluated by qRT-PCR. Data are given as mean ± SD of three independent experiments. Differences were 
assessed by Student’s t-test: *p < 0.05; **p < 0.01; ***p < 0.001.
Figure 5. Effect of recombinant hPCSK9 on TNF-α mRNA expression in LDLR−/− BMM. LDLR+/+ and 
LDLR−/− BMM were incubated with TNF-α 10 ng/ml (as positive control) or different concentrations of 
recombinant hPCSK9 (0.25, 0.5, 1 and 2.5 μg/ml). After 24 h, total RNA and protein extracts were prepared. 
LDLR receptor mRNA (A) and protein (B) expressions were evaluated by qRT-PCR and western blotting, 
respectively. (C) TNF-α mRNA levels were determined by qRT-PCR. (D) THP-1 macrophages were incubated 
with hPCSK9 (2.5 μg/ml) in the presence or absence of the JAK inhibitor (10 µM) and fatostatin (100 µM). Data 
are given as mean ± SD of three independent experiments. Differences vs basal (*) and between genotypes (†) 
were assessed by 1-way ANOVA: *p < 0.05; **p < 0.01; ***p < 0.001. †p < 0.05; ††p < 0.01; †††p < 0.001.
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accumulation. This evidence suggests a possible association between LDL-C lowering and anti-inflammatory 
effect on circulating monocytes28. In addition, the ATHEROREMO-IVUS study demonstrated a linear relation-
ship between PCSK9 plasma levels and both fraction and amount of necrotic core tissue in coronary atheroscle-
rosis, independently of serum LDL-cholesterol levels18.
In the attempt to define the molecular mechanism of the pro-inflammatory effect of PCSK9, we have utilized 
macrophages derived from LDLR null mice. From these analysis, we observed that in presence of the LDLR the 
induction of TNF-α by PCSK9 is massive. However, a significant effect was still present in BMM LDLR−/−. Thus, 
additional receptors targeted by PCSK9, such as CD3629, VLDLR, LRP-130 or ApoER231, could participate in 
the pro-inflammatory response. Our data are in agreement with in vitro12 and in vivo experimental settings32. 
By using chemical inhibitors, we also demonstrated that the proinflammatory effect of PCSK9 is dependent on 
the activation of JAK and SREBP pathways. Although the regulation of the intracellular molecular pathways by 
PCSK9 requires further investigations, it is relevant to note that THP-1 derived macrophages showed a nuclear 
localization of p65 NF-κB proinflammatory transcription factor, although at lower extent than the TNF-α. This 
evidence further support a pro-inflammatory function of PCSK9 as potential cytokine.
Native LDL, a natural LDLR ligand, has recently shown to promote the differentiation of monocytes to 
macrophages33. In particular, LDL facilitated the M1 polarization, blocked the ability of monocytes to polarize 
into M2 macrophages, and enhanced the inflammatory M1 response33. From this evidence, it is conceivable to 
hypothesize that LDL particles and PCSK9 activate similar intracellular signaling pathways by interacting with 
the LDLR, which induces a pro-inflammatory effect on macrophages.
By using a mouse model of bone marrow transplantation, Fazio et al., have investigated the effect of specific 
PCSK9 overexpression in macrophages on experimental atherosclerosis12. Despite no differences in lipid profile, 
the lesions of mice with macrophages expressing the PCSK9 transgene, showed an LDLR-dependent increase 
of pro-inflammatory monocytes12. Moreover, the expression of PCSK9 increased the presence of CD11b- and 
Ly6Chi-positive cells in spleens of apoE−/− mice and significantly improved the pro-inflammatory response to 
lipopolysaccharide (LPS)12. Our findings are in agreement with this study and further extend the observation of 
pro-inflammatory properties of PCSK9 in the absence of a co-stimulus, such as LPS. On this matter, it is impor-
tant to mention that lipoproteins and their receptors play a key role during sepsis as they favor the hepatic clear-
ance of endotoxins, such as LPS. Indeed, PCSK9 null mice show higher hepatic LDLR expression and improved 
clearance of bacterial endotoxin via the LDLR pathway, and a higher resistance to LPS-induced septic shock11.
In our study, together with pro-inflammatory cytokines, PCSK9 significantly induced two chemokines rele-
vant for monocyte recruitment in the atherosclerotic plaque, such as MCP-134 and CXCL235. From this in vitro 
observation, it is tempting to speculate that PCSK9 could promote a local inflammatory response by reinforcing 
the recruitment of circulating monocytes and neutrophils in the atherosclerotic plaque. Nevertheless, additional 
and more specific experiments need to be performed in order to demonstrate this action.
In the attempt to translate our findings to a clinical setting, we performed a correlation analysis between 
the plasma levels of PCSK9 and TNF-α in a population of healthy subjects recruited in the Brisighella Heart 
Study17. For the analysis, we excluded subjects affected by chronic inflammatory disorders, and those chronically 
assuming non-steroidal antinflammatory drugs, systemic corticosteroids, or immunosuppressants. Interestingly, 
a positive association between the two factors was found, supporting the possibility that either TNF-α drives the 
expression of PCSK936, or vice versa PCSK9 induces TNF-α.
In conclusion, in the present study we provided evidence for a direct pro-inflammatory effect of PCSK9 on 
macrophages. A pathophysiological relevance of this in vitro observation requires further investigations.
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